David Healy and Robert Whitaker address suicide rate in New Zealand

I’m passing on this e-mail from Vince Boehm and video link that I received in my maibox today via ISEPP.

“Risk of suicide” was one of the many reasons given by my son’s psychiatrists for wanting to keep him on medications, not that he was suicidal, but because “statistics show that people with a diagnosis of schizophrenia have an increased risk for suicide during the first five years after diagnosis.”  I always felt that the specter of suicide was invoked often for the wrong reasons — not because patients were suicidal, but in order to keep them meds compliant. I was being made to feel irresponsible by continuing to inisist that my son was unlikely to commit suicide and I would prefer to work with him in non-drug interventions. The problem is, how do one ever really know that someone else is or is not suicidal?  That’s where I feel drug companies have gained the advantage. You don’t know, and nobody wants to assume the risk, so medications are prescribed as some sort of “insurance policy.”

People can and do commit suicide while on meds and when off meds, so it’s kind of murky to now whether the meds would have prevented it or caused it. On the other hand, there is valid scientific concern about the effect of antidepressants on suicide ideation in children and teenagers because antidepressants are being used off-label and little to no research had been done for this age group before this practice became widespread.

Here’s the e-mail from Vince Boehm about the video link:

CASPER (Community Action on Suicide Prevention Education & Research), the New Zealand organization organized by two mothers who lost children to suicide, invited two of our prominent list members to present at their conference this past month.   New Zealand has the highest rate of youth suicide in the OECD, twice the rate of the US and Australia and five times the rate of the UK. More young people in New Zealand die of suicide than all medical causes combined, with 10% of the deaths of New Zealand’s 10-14 year-olds being suicides.

David Healy is an Irish psychiatrist who is a professor in Psychological Medicine at Cardiff University School of Medicine, Wales.  He became the center of controversy concerning the influence of the pharmaceutical industry on medicine and academia. For most of his career Healy has held the view that Prozac and SSRIs (selective serotonin re-uptake inhibitors) can lead to suicide and has been critical of the amount of ghost writing in the current scientific literature.

In his segment of this compelling video, Healy delivers a powerful indictment of suicide and violence caused by psychiatric meds. Robert Whitaker is a friend and a former medical writer at the Albany Times Union newspaper.  In 1992, he was a Knight Science Journalism fellow at MIT.  Following that he became director of publications at Harvard Medical School. In 1994 he co-founded a publishing company, CenterWatch, that covered the pharmaceutical clinical trials industry. CenterWatch was acquired by Medical Economics, a division of The Thomson Corporation, in 1998. His articles on psychiatry and the pharmaceutical industry have won a George Polk Award for Medical Writing. and a National Association of Science Writers’ Award for best magazine article. In 1998, he co-wrote a series on abuses in psychiatric research that was a finalist for the Pulitzer Prize in Public Service. He is the author of four books. His most recent book is Anatomy of an Epidemic: Magic Bullets, Psychiatric Drugs, and the Astonishing Rise of Mental Illness in America. His Mad in America has become a classic and belongs in your library.

These two books are destined to be mental health’s Silent Spring, the book that launched the environmental movement.

Abnormal is the new black

I received this message in my in-box from Vince Boehm, a psych rights activist:

**** note: This is a private list. I send out alerts, useful news items, and comment to a group of mental health professionals, decision makers and activists. (OK to repost and to include this header and comments). If you do not want to receive any of these emails, please let me know. To preserve privacy, I blind copy the entire list. Vince Boehm ****

While this article is obviously framed in terms favorable to the industry, and similar reports with like numbers have been published for the U.S. market as well, I have a hypothetical question.

With the percentages of labeled people seemingly creeping up relentlessly towards a 51% majority, what happens when these numbers cross that line?

Will then the “abnormal” become “normal”?

Just a thought.

Vince
http://news.yahoo.com/nearly-40-pct-europeans-suffer-mental-illness-230827577.html

Nearly 40 percent of Europeans suffer mental illness

LONDON (Reuters) – Europeans are plagued by mental and neurological illnesses, with almost 165 million people or 38 percent of the population suffering each year from a brain disorder such as depression, anxiety, insomnia or dementia, according to a large new study.

With only about a third of cases receiving the therapy or medication needed, mental illnesses cause a huge economic and social burden — measured in the hundreds of billions of euros — as sufferers become too unwell to work and personal relationships break down.

“Mental disorders have become Europe’s largest health challenge of the 21st century,” the study’s authors said.

At the same time, some big drug companies are backing away from investment in research on how the brain works and affects behavior, putting the onus on governments and health charities to stump up funding for neuroscience.

“The immense treatment gap … for mental disorders has to be closed,” said Hans Ulrich Wittchen, director of the institute of clinical psychology and psychotherapy at Germany’s Dresden University and the lead investigator on the European study.

“Those few receiving treatment do so with considerable delays of an average of several years and rarely with the appropriate, state-of-the-art therapies.”

Wittchen led a three-year study covering 30 European countries — the 27 European Union member states plus Switzerland, Iceland and Norway — and a population of 514 million people.

A direct comparison of the prevalence of mental illnesses in other parts of the world was not available because different studies adopt varying parameters.

Wittchen’s team looked at about 100 illnesses covering all major brain disorders from anxiety and depression to addiction to schizophrenia, as well as major neurological disorders including epilepsy, Parkinson’s and multiple sclerosis.

The results, published by the European College of Neuropsychopharmacology (ENCP) on Monday, show an “exceedingly high burden” of mental health disorders and brain illnesses, he told reporters at a briefing in London.

Mental illnesses are a major cause of death, disability, and economic burden worldwide and the World Health Organization predicts that by 2020, depression will be the second leading contributor to the global burden of disease across all ages.

Wittchen said that in Europe, that grim future had arrived early, with diseases of the brain already the single largest contributor to the EU’s burden of ill health.

The four most disabling conditions — measured in terms of disability-adjusted life years or DALYs, a standard measure used to compare the impact of various diseases — are depression, dementias such as Alzheimer’s disease and vascular dementia, alcohol dependence and stroke.

The last major European study of brain disorders, which was published in 2005 and covered a smaller population of about 301 million people, found 27 percent of the EU adult population was suffering from mental illnesses.

Although the 2005 study cannot be compared directly with the latest finding — the scope and population was different — it found the cost burden of these and neurological disorders amounted to about 386 billion euros ($555 billion) a year at that time. Wittchen’s team has yet to finalize the economic impact data from this latest work, but he said the costs would be “considerably more” than estimated in 2005.

The researchers said it was crucial for health policy makers to recognize the enormous burden and devise ways to identify potential patients early — possibly through screening — and make treating them quickly a high priority.

“Because mental disorders frequently start early in life, they have a strong malignant impact on later life,” Wittchen said. “Only early targeted treatment in the young will effectively prevent the risk of increasingly largely proportions of severely ill…patients in the future.”

David Nutt, a neuropsychopharmacology expert at Imperial College London who was not involved in this study, agreed.

“If you can get in early you may be able to change the trajectory of the illness so that it isn’t inevitable that people go into disability,” he said. “If we really want not to be left with this huge reservoir of mental and brain illness for the next few centuries, then we ought to be investing more now.”

(Reporting by Kate Kelland; Editing by Matthew Jones)